Your browser doesn't support javascript.
loading
An optimized messenger RNA vaccine candidate protects non-human primates from Zika virus infection.
Bollman, Brooke; Nunna, Naveen; Bahl, Kapil; Hsiao, Chiaowen Joyce; Bennett, Hamilton; Butler, Scott; Foreman, Bryant; Burgomaster, Katherine E; Aleshnick, Maya; Kong, Wing-Pui; Fisher, Brian E; Ruckwardt, Tracy J; Morabito, Kaitlyn M; Graham, Barney S; Dowd, Kimberly A; Pierson, Theodore C; Carfi, Andrea.
  • Bollman B; Moderna, Inc., Cambridge, MA, USA. Brooke.Bollman@modernatx.com.
  • Nunna N; Moderna, Inc., Cambridge, MA, USA.
  • Bahl K; Moderna, Inc., Cambridge, MA, USA.
  • Hsiao CJ; Moderna, Inc., Cambridge, MA, USA.
  • Bennett H; Moderna, Inc., Cambridge, MA, USA.
  • Butler S; Takeda, Cambridge, MA, USA.
  • Foreman B; Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Burgomaster KE; Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Aleshnick M; Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Kong WP; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Fisher BE; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Ruckwardt TJ; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Morabito KM; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Graham BS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Dowd KA; Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Pierson TC; Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Carfi A; Moderna, Inc., Cambridge, MA, USA.
NPJ Vaccines ; 8(1): 58, 2023 Apr 20.
Article en En | MEDLINE | ID: mdl-37080988
ABSTRACT
Zika virus (ZIKV), an arbovirus transmitted by mosquitoes, was identified as a cause of congenital disease during a major outbreak in the Americas in 2016. Vaccine design strategies relied on limited available isolate sequence information due to the rapid response necessary. The first-generation ZIKV mRNA vaccine, mRNA-1325, was initially generated and, as additional strain sequences became available, a second mRNA vaccine, mRNA-1893, was developed. Herein, we compared the immune responses following mRNA-1325 and mRNA-1893 vaccination and reported that mRNA-1893 generated comparable neutralizing antibody titers to mRNA-1325 at 1/20th of the dose and provided complete protection from ZIKV challenge in non-human primates. In-depth characterization of these vaccines indicated that the observed immunologic differences could be attributed to a single amino acid residue difference that compromised mRNA-1325 virus-like particle formation.
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2023 Tipo del documento: Article